The increasing number of people with type 2 diabetes will increase the Non-insulin Diabetes Therapeutics Market Growth

The Non-insulin Diabetes Therapeutics Market share is expected to grow by USD 22.95 billion accelerating at a CAGR of 10% during the forecast period. Due to the generic symptoms associated with the disease, the early diagnosis of type 2 diabetes is often a challenge. Hence, the increasing number of people with type 2 diabetes will drive the growth of the non-insulin diabetes therapeutics market during the forecast period. 

Outlook the Sample Report to understand the factors impacting the growth of the Non-insulin Diabetes Therapeutics Market 

"The Increasing number of people with type 2 diabetes will drive the growth prospects for the global Non-insulin Diabetes Therapeutics Market in the forthcoming years. 33% of the market’s growth will originate from North America during the forecast period."

Non-insulin Diabetes Therapeutics Market: Segment Highlights

• Type Segmentation: Coronary stents, PTCA balloon catheters, Interventional guidewires, Interventional imaging systems, and Others 
• Coronary stents segment dominated the global non-insulin diabetes therapeutics market in 2020 however, market growth in this segment will be slower than the growth of the market in the interventional imaging systems segment.
• The growing aging population, the uptake of bioabsorbable stents, and the demand for PCI procedures, in particular, is expected to hasten market growth in the coronary stents segment during the forecast period.

Non-insulin Diabetes Therapeutics Market: Competitive Analysis

• The Non-insulin Diabetes Therapeutics Market is concentrated due to the presence of several vendors.
• Market vendors focused on market expansion, innovations, and expansion of distribution networks.
• Abbott Laboratories, AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, and Sanofi SA are some of the major market participants. The growing demand for MI procedures will offer immense growth opportunities to the non-insulin diabetes therapeutics market. However, the high cost of non-insulin diabetes therapeutics procedures will challenge the growth of the market. 

Technavio provides custom research reports with basic insights on the upcoming developments along with pipeline analysis of vendor operations and the impact of government regulations with respect to the industry, region, and supply chain operations. Download the Sample Report 

The report provides insights into the following FAQs:

1. What is the market CAGR?
   The market is accelerating at a CAGR of 10%.
2. What is the incremental growth of the market?
   The market is expected to grow by USD 22.95 billion during 2020-2025.
3. What is a key factor driving this market?
   The increasing number of people with type 2 diabetes will drive market growth over the forecast period.
4. Which is the leading geographic region for this market?
   33% growth will originate from North America.
5. Who are the leading market vendors?
   The leading vendors in this market are Abbott Laboratories, AstraZeneca Plc, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, and Sanofi SA.
6. What are the market segments covered in this report?
   The market is segmented by Type (DPP4 inhibitor, GLP-1 receptor agonist, SGLT2 inhibitor, and Others) and Geography (North America, Europe, Asia, and ROW).